Treatment for Mild Plaque Psoriasis on the Face and Neck
For facial and neck psoriasis, use topical tacalcitol ointment or calcipotriene combined with hydrocortisone for 8 weeks as your first-line treatment. 1
Primary Recommendation
The 2021 Joint AAD-NPF Guidelines provide a Strength B recommendation specifically for facial psoriasis treatment 1:
- Topical tacalcitol ointment (if available in your region), OR
- Calcipotriene combined with hydrocortisone for 8 weeks
This recommendation is particularly important for facial and neck areas because these sensitive skin sites require gentler approaches than trunk or extremity psoriasis.
Alternative Option for Facial Involvement
Tacrolimus 0.1% ointment can be considered as an off-label alternative for up to 8 weeks (Strength B recommendation) 1. In a double-blind RCT of 167 patients with facial psoriasis, 65% of patients achieved clear or almost clear skin after 8 weeks with tacrolimus 0.1% ointment compared to 31% with placebo 1.
Important Caveat About Tacrolimus
While tacrolimus carries an FDA boxed warning regarding theoretical malignancy risk (skin cancer and lymphoma), there is no evidence showing an increased risk of malignancy with topical use 1. The warning stems from systemic use data and animal studies, not from topical application in humans. Common side effects include burning and pruritus, which typically improve with continued use and can be minimized by avoiding application to moist skin 1.
Why Not Standard Combination Therapy?
You'll notice the guidelines specifically recommend lower-potency corticosteroids (hydrocortisone) for facial psoriasis rather than the potent betamethasone dipropionate combinations recommended for body psoriasis 1. This is critical because:
- Facial skin is thinner and more prone to corticosteroid-induced atrophy
- Risk of striae, telangiectasia, and perioral dermatitis is higher on the face
- The face and neck require more conservative corticosteroid selection
Treatment Algorithm for Face and Neck
First-line (8 weeks):
- Calcipotriene + hydrocortisone combination, OR
- Tacalcitol ointment (if available)
Alternative first-line (8 weeks):
- Tacrolimus 0.1% ointment (off-label)
If inadequate response:
- Consider pimecrolimus (off-label, Strength B recommendation for inverse/facial psoriasis) 1
- Evaluate for systemic therapy if disease extends beyond face/neck or significantly impacts quality of life
Critical Pitfalls to Avoid
- Do not use potent or superpotent corticosteroids on the face - stick with low-potency options like hydrocortisone
- Avoid salicylic acid with calcipotriene - the acidic pH inactivates calcipotriene and reduces effectiveness 1
- Do not apply vitamin D analogues before phototherapy if combining treatments - apply after to avoid UVA inactivation 1
- Counsel patients about tacrolimus burning - this typically improves with continued use and shouldn't lead to premature discontinuation 1
Evidence Quality
The facial psoriasis recommendations are based on Level I-II evidence from randomized controlled trials 1. While the strength of recommendation is B rather than A (reflecting somewhat less robust evidence than for body psoriasis), these remain the best-studied and guideline-endorsed approaches specifically for facial involvement.